返回 
加入收藏
苯磺酸氨氯地平联合赖诺普利氢氯噻嗪与阿托伐他汀治疗重度原发性高血压合并颈动脉粥样硬化的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 苯磺酸氨氯地平联合赖诺普利氢氯噻嗪与阿托伐他汀治疗重度原发性高血压合并颈动脉粥样硬化的临床观察 |
| TITLE： | |
| 摘要： | 目的： 观察苯磺酸氨氯地平联合赖诺普利氢氯噻嗪与阿托伐他汀治疗重度原发性高血压合并颈动脉粥样硬化的临床疗效和安全性。方法：90例重度原发性高血压合并颈动脉粥样硬化患者以抽签法分为对照组（45例）和观察组（45例）。两组患者入院后均给予阿托伐他汀钙片20 mg/次，口服，每日1次；同时，对照组患者给予苯磺酸氨氯地平片5 mg/次，口服，每日1次；观察组患者在对照组治疗基础上加服赖诺普利氢氯噻嗪片10 mg/次，口服，每日1次。两组疗程均为8周。比较两组患者临床疗效，治疗前后血压水平、颈动脉内膜中层厚度（IMT）、颈动脉峰值流速（PV）、血清超敏C反应蛋白（hs-CRP） 、血浆肿瘤坏死因子α（TNF-α）水平，记录治疗期间不良反应发生情况。结果：观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）；治疗前，两组患者收缩压（SBP）、舒张压（DBP）、IMT、PV、hs-CRP、TNF-α水平比较差异均无统计学意义（P＞0.05）。治疗后，两组患者SBP、DBP、IMT、PV、hs-CRP、TNF-α水平显著低于同组治疗前，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：苯磺酸氨氯地平联合赖诺普利氢氯噻嗪与阿托伐他汀治疗重度原发性高血压合并颈动脉粥样硬化可有效控制患者血压水平，延缓动脉粥样硬化病情进展，降低机体炎症反应程度，且未增加不良反应的发生，安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy and safety of amlodipine besylate combined with lisinopril and hydrochlorothiazide， atorvastatin in the treatment of severe primary hypertension complicating with carotid atherosclerosis. METHODS： 90 patients with severe primary hypertension complicating with carotid atherosclerosis were divided into control group （45 cases） and observation group （45 cases） according to random lottery form. Both groups were given Atorvastatin calcium tablet 20 mg/time orally， qd； control group was additionally given Amlodipine besylate tablet 5 mg/time orally， qd； observation group was additionally given Lisinopril and hydrochlorothiazide tablet 10 mg/time orally， qd， on the basis of control group. Both groups were treated for 8 weeks. Clinical efficacies of 2 groups were compared as well as blood pressure level， IMT， PV of carotid atherosclerosis， hs-CRP， TNF-α before and after treatment. The occurrence of ADR was recorded. RESULTS： Total response rate of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. Before treatment， there were no significant differences in SBP，DBP，IMT，PV， hs-CRP and TNF-α level（P＞0.05）. After treatment， the levels of SBP， DBP， IMT， PV， hs-CRP and TNF-α level in 2 groups were significantly lower than before； the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Amlodipine besylate combined with lisinopril and hydrochlorothiazide， atorvastatin in the treatment of primary hypertension complicating with carotid atherosclerosis can effectively control the blood pressure level， delay the progression process of carotid atherosclerosis， reduce the inflammatory reaction degree， but dose not increase the occurrence of ADR with good safety. |
| 期刊： | 2017年第28卷第9期 |
| 作者： | 刘俊燕，栗娜 |
| AUTHORS： | LIU Junyan，LI Na |
| 关键字： | 钙拮抗药；血管紧张素转化酶抑制剂；阿托伐他汀；原发性高血压；颈动脉粥样硬化；苯磺酸氨氯地平；赖诺普利氢氯噻嗪 |
| KEYWORDS： | Calcium antagonists； Angiotensin-converting enzyme inhibitor； Atorvastetin； Primary hypertension； Carotid atherosclerosis； Amlodipine besylate； Lisinopril and hydrochlorothiazide |
| 阅读数： | 420 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
